OBJECTIVE: To compare the prevalence, awareness, treatment, and control of hypertension in a population-representative sample of adults with type 1 diabetes and comparable nondiabetic control subjects. RESEARCH DESIGN AND METHODS: In 2000-2002, the Coronary Artery Calcification in Type 1 Diabetes Study enrolled 1,416 individuals aged 19-56 years with no known history of coronary artery disease: 652 type 1 diabetic patients (46% male, mean age 37 years) and 764 nondiabetic control subjects (50% male, mean age 39 years). Subjects were asked if they had been told by a physician that they had hypertension or were on a blood pressure medication. Blood pressure was measured using standardized Joint National Committee (JNC) protocol. RESULTS: Type 1 diabetic subjects, compared with nondiabetic subjects, had higher rates of hypertension prevalence (43 vs. 15%, P < 0.001), awareness (53 vs. 45%, P = 0.11), treatment (87 vs. 47%, P < 0.001), and control (55 vs. 32%, P < 0.001) for the JNC 6 goal (130/85 mmHg). Only 42% of all type 1 diabetic hypertensive subjects met the new JNC 7 goal (130/80 mmHg). Type 1 diabetic subjects had better blood pressure control (72 vs. 32%, P < 0.0001), using 140/90 mmHg as a common measure. The majority of treated subjects were on a single antihypertensive agent (75 vs. 64%). CONCLUSIONS: Subjects with type 1 diabetes have higher rates of hypertension prevalence, treatment, and control than nondiabetic subjects. However, hypertension remains largely uncontrolled, even if treated in high-risk populations, such as type 1 diabetic subjects and undiagnosed individuals in the general population. Achieving more stringent blood pressure goals will require increased attention and may necessitate the use of multiple antihypertensive agents.
OBJECTIVE: To compare the prevalence, awareness, treatment, and control of hypertension in a population-representative sample of adults with type 1 diabetes and comparable nondiabetic control subjects. RESEARCH DESIGN AND METHODS: In 2000-2002, the Coronary Artery Calcification in Type 1 Diabetes Study enrolled 1,416 individuals aged 19-56 years with no known history of coronary artery disease: 652 type 1 diabeticpatients (46% male, mean age 37 years) and 764 nondiabetic control subjects (50% male, mean age 39 years). Subjects were asked if they had been told by a physician that they had hypertension or were on a blood pressure medication. Blood pressure was measured using standardized Joint National Committee (JNC) protocol. RESULTS: Type 1 diabetic subjects, compared with nondiabetic subjects, had higher rates of hypertension prevalence (43 vs. 15%, P < 0.001), awareness (53 vs. 45%, P = 0.11), treatment (87 vs. 47%, P < 0.001), and control (55 vs. 32%, P < 0.001) for the JNC 6 goal (130/85 mmHg). Only 42% of all type 1 diabetic hypertensive subjects met the new JNC 7 goal (130/80 mmHg). Type 1 diabetic subjects had better blood pressure control (72 vs. 32%, P < 0.0001), using 140/90 mmHg as a common measure. The majority of treated subjects were on a single antihypertensive agent (75 vs. 64%). CONCLUSIONS: Subjects with type 1 diabetes have higher rates of hypertension prevalence, treatment, and control than nondiabetic subjects. However, hypertension remains largely uncontrolled, even if treated in high-risk populations, such as type 1 diabetic subjects and undiagnosed individuals in the general population. Achieving more stringent blood pressure goals will require increased attention and may necessitate the use of multiple antihypertensive agents.
Authors: David M Maahs; Nancy A West; Jean M Lawrence; Elizabeth J Mayer-Davis Journal: Endocrinol Metab Clin North Am Date: 2010-09 Impact factor: 4.741
Authors: Philip Ljunggren; David M Maahs; Per Johansson; Johnny Ludvigsson; Laura Pyle; Rachel Sippl; R Paul Wadwa; Janet Snell-Bergeon Journal: J Diabetes Complications Date: 2016-03-11 Impact factor: 2.852
Authors: P Bjornstad; T Costacou; R G Miller; D M Maahs; M J Rewers; T J Orchard; J K Snell-Bergeon Journal: Diabet Med Date: 2017-08-14 Impact factor: 4.359
Authors: Petter Bjornstad; David M Maahs; Marian Rewers; Richard J Johnson; Janet K Snell-Bergeon Journal: J Diabetes Complications Date: 2014-07-04 Impact factor: 2.852
Authors: David M Maahs; Janet K Snell-Bergeon; John E Hokanson; Gregory L Kinney; Tomas Berl; Marian Rewers; Lorraine G Ogden Journal: Diabetes Technol Ther Date: 2010-01 Impact factor: 6.118
Authors: Petter Bjornstad; Janet K Snell-Bergeon; Kimberly McFann; R Paul Wadwa; Marian Rewers; Christopher J Rivard; Diana Jalal; Michel B Chonchol; Richard J Johnson; David M Maahs Journal: J Diabetes Complications Date: 2013-12-27 Impact factor: 2.852
Authors: Janet K Snell-Bergeon; Dana Dabelea; Lorraine G Ogden; John E Hokanson; Gregory L Kinney; James Ehrlich; Marian Rewers Journal: J Clin Endocrinol Metab Date: 2008-03-18 Impact factor: 5.958
Authors: David M Maahs; John E Hokanson; Hong Wang; Gregory L Kinney; Janet K Snell-Bergeon; Ashley East; Bryan C Bergman; Irene E Schauer; Marian Rewers; Robert H Eckel Journal: Diabetes Date: 2010-04-14 Impact factor: 9.461
Authors: Kerri L Cavanaugh; Sharon Stein Merkin; Laura C Plantinga; Nancy E Fink; John H Sadler; Neil R Powe Journal: Am J Kidney Dis Date: 2008-04-02 Impact factor: 8.860